Nektar Therapeutics to Participate in Two Investor Conferences in September

About this update from Nektar Therapeutics

SAN FRANCISCO , Sept. 3, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its participation in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City and the Stifel Virtual Immunology and Inflammation Forum being held September 15-16, 2025 . H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . Replays of the presentations will be available for 30 days. If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California . For further information, visit www.nektar.com and follow Nektar on LinkedIn. Contact: For Investors: Vivian Wu of Nektar Therapeutics628-895-0661 For Media: Madelin Hawtin LifeSci Communications 603-714-2638 [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september-302545833.html SOURCE Nektar Therapeutics

View stock analysis, news, and events for Nektar Therapeutics